During the last session, Mersana Therapeutics Inc (NASDAQ:MRSN)’s traded shares were 3.58 million, with the beta value of the company hitting 1.63. At the end of the trading day, the stock’s price was $0.61, reflecting an intraday loss of -5.58% or -$0.04. The 52-week high for the MRSN share is $6.28, that puts it down -929.51 from that peak though still a striking 19.67% gain since the share price plummeted to a 52-week low of $0.49. The company’s market capitalization is $75.27M, and the average intraday trading volume over the past 10 days was 5.0 million shares, and the average trade volume was 4.62 million shares over the past three months.
Mersana Therapeutics Inc (MRSN) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.36. MRSN has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.16.
Mersana Therapeutics Inc (NASDAQ:MRSN) trade information
Mersana Therapeutics Inc (MRSN) registered a -5.58% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -5.58% in intraday trading to $0.61, hitting a weekly high. The stock’s 5-day price performance is -10.89%, and it has moved by -3.90% in 30 days. Based on these gigs, the overall price performance for the year is -84.50%. The short interest in Mersana Therapeutics Inc (NASDAQ:MRSN) is 9.47 million shares and it means that shorts have 1.02 day(s) to cover.
The consensus price target of analysts on Wall Street is $3, which implies an increase of 79.67% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $3 and $3 respectively. As a result, MRSN is trading at a discount of -391.8% off the target high and -391.8% off the low.
Mersana Therapeutics Inc (MRSN) estimates and forecasts
In the rating firms’ projections, revenue will decrease -15.77% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 7.64M as predicted by 10 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to 5.2M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 10.7M and 9.24M respectively. In this case, analysts expect current quarter sales to shrink by -28.60% and then drop by -43.78% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 11.93%. While earnings are projected to return 58.87% in 2025, the next five years will return 20.92% per annum.
MRSN Dividends
Mersana Therapeutics Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 11.33 million shares, is of VR ADVISER, LLC’s that is approximately 9.3292% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $22.77 million.
Also, the Mutual Funds coming in first place with the largest holdings of Mersana Therapeutics Inc (MRSN) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 3.47 shares. This amounts to just over 2.81 percent of the company’s overall shares, with a $2.11 million market value. The same data shows that the other fund manager holds slightly less at 3.22, or about 2.60% of the stock, which is worth about $1.96 million.
